Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + nimotuzumab
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cadonilimab + nimotuzumab is a combination therapy being investigated for recurrent or metastatic cervical cancer as a second-line or later therapy. Cadonilimab is a humanized bispecific antibody that targets both PD-1 and CTLA-4 immune checkpoints. Nimotuzumab is a humanized IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR). This combination aims to leverage both immune checkpoint inhibition and EGFR targeting to treat advanced cervical cancer.
- Brand names
- KaitaniTaixinsheng
- Other names
- cadonilimab + nimotuzumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on cadonilimab + nimotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + nimotuzumab.